IDEAYA Biosciences Inc. (IDYA) has announced positive clinical data from the 30 mg expansion dose of its phase II trial of IDE397 monotherapy in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients.
Among the 18 evaluable patients in the trial, the Overall Response Rate was 39% and the Disease Control Rate was about 94%. Furthermore, tumor shrinkage was observed in approximately 78% of patients (14 out of 18), and the ctDNA molecular response rate was an impressive 81%, according to the company.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.